Research / Clinical
Summary
|
|
 |
Barbara Jung, MD
Assistant Adjunct Professor, Medicine
Tumor Growth, Invasion & Metastasis Program
Contact by Email
|
Diseases/Research Topics
Activin, Colon Cancer, Growth Factor
Activin is a growth suppressive ligand of the TGFbeta superfamily, and its signaling pathway is targeted for disruption in colon cancers. Dr. Jung has recently shown that the receptor encoded by ACVR2 is frameshift mutated in more than 80% of microsatellite unstable and a subset of microsatellite stable colon cancers, causing loss of ACVR2 protein expression. Further, there is evidence of modulation of the growth suppressive effect of activin via mitogenic signaling operative on colon cancers. Her current focus is to decipher the mechanism of ACVR2 loss in colon cancer, as well as the effects of abrogated activin signaling on colon carcinogenesis and its modulation via activated mitogenic signaling.
Update Summary via ONcLINE (password required)
Click here to request a
new or forgotten password
|
